

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

**(1) APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND
INDEPENDENT NON-EXECUTIVE DIRECTOR**
**(2) RE-DESIGNATION OF NON-EXECUTIVE DIRECTOR
AND**
(3) APPOINTMENT OF VICE PRESIDENTS

The Board hereby announces that, with effect from July 10, 2024:

- (i) Mr. Cen Jialin will be appointed as a non-executive Director;
- (ii) Dr. Tao Qian will be appointed as an independent non-executive Director;
- (iii) Dr. Qian Weizhu, currently a non-executive Director of the Company, will be re-designated as an executive Director and will be appointed as a vice president of the Company; and
- (iv) Mr. Li Yunfeng will be appointed as a vice president of the Company and no longer holds the position of chief financial officer of the Company.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of Mabpharm Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes.

I. APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR

With effect from July 10, 2024, Mr. Cen Jialin (“**Mr. Cen**”) and Dr. Tao Qian (“**Dr. Tao**”) will be appointed as a non-executive Director and an independent non-executive Director respectively.

The biographical details of Mr. Cen and Dr. Tao are set out below.

Mr. Cen Jialin (岑佳麟), aged 49, currently serves as an executive director of CDH Investments (鼎暉投資). From August 2002 to September 2004, Mr. Cen served as the manager of the operation and procurement department in Shenzhen branch of AEON (China) Co., Ltd. (永旺(中國)商業有限公司). From January 2006 to April 2007, Mr. Cen served as the general manager in charge of the retail division in Chongqing branch and Maoming branch of CapitaLand China (凱德集團). From March 2007 to March 2018, Mr. Cen served as the general manager of Skycity Group (天城集團). Mr. Cen has been an executive director of CDH Investments (鼎暉投資) since April 2018.

Mr. Cen obtained a bachelor’s degree in finance and securities from Shenzhen University (深圳大學) in July 1999 and obtained a master’s degree in business administration from Washington University in St. Louis in December 2012.

The Company has entered into a letter of appointment with Mr. Cen for his appointment as a non-executive Director for a term of three years commencing from July 10, 2024, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company (the “**Articles of Association**”) and the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). In accordance with Mr. Cen’s letter of appointment, Mr. Cen will not receive any director’s fee or other remuneration for holding his office as a non-executive Director except for any discretionary bonus as determined by the Board.

Save as disclosed above, as at the date of this announcement, Mr. Cen (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the the Securities and Futures Ordinance, Chapter 571 of the laws of Hong Kong (the “**SFO**”); and (iv) does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries.

Mr. Cen has confirmed that he has obtained legal advice from a firm of solicitors under Rule 3.09D of the Listing Rules and has confirmed that he understood his obligations as a Director of the Company.

Save as disclosed above, there is no other matter in relation to the appointment of Mr. Cen that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or the Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

Dr. Tao Qian (陶謙), aged 58, currently serves as a professor of department of clinical oncology at The Chinese University of Hong Kong. Dr. Tao is a leader in cancer epigenetics and tumor suppressor genes study in Asia and has published 189 journal articles and 5 book chapters with over 14,000 citations. Dr. Tao served as a research associate at Shantou University Medical College (汕頭大學醫學院) from 1988 to 1990 and a lecturer from 1990 to 1991 at the aforementioned university. Dr. Tao served as an assistant professor of department of oncology at Johns Hopkins School of Medicine from February 1999 to August 2004 and a consultant from August 2004 to November 2006 at the aforementioned university. Dr. Tao served as an adjunct associate professor of department of microbiology at the National University of Singapore from 2001 to 2004. Dr. Tao also served as an associate professor of department of clinical oncology at The Chinese University of Hong Kong from August 2004 to August 2008.

Dr. Tao obtained a bachelor's degree in biology from Hunan Normal University (湖南師範大學) in July 1985 and obtained a master degree in genetics from Xiamen University (廈門大學) in August 1988. Dr. Tao was awarded a doctor of philosophy in molecular pathology and virology from The University of Hong Kong in November 1996 and has been a postdoctoral fellow at Sidney Kimmel Comprehensive Cancer Center from September 1995 to February 1999.

The Company has entered into a letter of appointment with Dr. Tao for his appointment as an independent non-executive Director for a term of two years commencing from July 10, 2024, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association and the Listing Rules. Dr. Tao will receive an annual director's fee of HK\$120,000, which is fixed with reference to his duties and responsibilities within the Company, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. Tao (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO; and (iv) does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries.

Dr. Tao has confirmed that he has obtained legal advice from a firm of solicitors under Rule 3.09D of the Listing Rules and has confirmed that he understood his obligations as a Director of the Company.

Dr. Tao has confirmed that (i) he has met the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interests in the business of the Company's core connected persons (as defined in the Listing Rules); and (iii) there are no other factors which might affect his independence.

Save as disclosed above, there is no other matter in relation to the appointment of Dr. Tao that needs to be brought to the attention of the Shareholders or the Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

II. RE-DESIGNATION OF NON-EXECUTIVE DIRECTOR

The board is pleased to announce that Dr. Qian Weizhu (“**Dr. Qian**”), currently a non-executive Director of the Company, will be re-designated as an executive Director and will be appointed as a vice president of the Company.

The biographical details of Dr. Qian are set out below.

Dr. Qian Weizhu (錢衛珠), aged 48, was appointed as a non-executive director of the Company and a director of Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) (“**Taizhou Pharmaceutical**”) and Shanghai Shengheng Biotechnology Limited* (上海晟珩生物技術有限公司) (“**Shengheng Biotech**”) in November 2023 and is responsible for participating in the formulation of the Group’s business and corporate strategies. Dr. Qian has more than 25 years of experience in oncology and biology fields. Dr. Qian was employed at the Cancer Institute of Second Military Medical University (第二軍醫大學) (currently known as People’s Liberation Army Navy Medical University (中國人民解放軍海軍軍醫大學)) from 1994 to 2013, primarily responsible for biotechnology research and development. Dr. Qian consecutively served as deputy general manager and general manager of Shanghai Zhangjiang Biotechnology Co., Ltd.* (上海張江生物技術有限公司) (“**Zhangjiang Biotech**”) from January 2014 to July 2017. Dr. Qian worked as a director and general manager in Shanghai Biomabs Pharmaceuticals Co., Ltd. (上海百邁博製藥有限公司) (“**Biomabs**”) from October 2015 to August 2018 and from December 2020 to October 2023, and as the vice president of Shanghai Mabstar Biotechnology Co., Ltd. (上海邁昂星生物技術有限公司) from November 2023 to July 2024. Dr. Qian also served as general manager in Shanghai Sinomab Biotechnology Co., Ltd.* (上海邁泰君奧生物技術有限公司) (“**MTJA**”) from February 2016 to August 2018. Dr. Qian was a legal representative of Shanghai Guojian Biotechnology Research Institute (上海國健生物技術研究院) from February 2015 to September 2018. Dr. Qian joined our Group in February 2015, and served consecutively as a director and chairman of the board of directors in Taizhou Pharmaceutical from February 2015 to October 2020, during which she had been deputy general manager and general manager of Taizhou Pharmaceutical consecutively from February 2015 to August 2018. Dr. Qian served as a director and general manager of Shengheng Biotech from August 2018 to October 2020. Dr. Qian served as the executive director and chief executive officer of the Company from July 2018 to October 2020 and served as a member of the nomination committee of the Company from the listing date of the Company (being May 31, 2019) to October 2020. Dr. Qian is the spouse of Dr. Hou Sheng (侯盛), one of the executive directors of the Company.

Dr. Qian obtained a master’s degree in biochemistry and molecular biology in June 2003 from Second Military Medical University (第二軍醫大學) (currently known as People’s Liberation Army Navy Medical University (中國人民解放軍海軍軍醫大學)) and was awarded a doctorate degree in oncology in June 2011 from the aforementioned university.

The Company has entered into a service contract with Dr. Qian for her appointment as an executive Director for a term of three years commencing from July 10, 2024, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association and the Listing Rules. In accordance with Dr. Qian’s service contract, Dr. Qian is entitled to a director’s fee of RMB850,000 per annum and discretionary bonus as determined by the Board. Her emoluments were recommended by the remuneration committee of the Company and approved by the Board with reference to her duties and responsibilities as well as her qualifications, experience and the prevailing market conditions.

As at the date of this announcement, Dr. Qian is beneficially interested in 29,642,137 underlying shares, representing approximately 0.72% of the issued share capital of the Company within the meaning of Part XV of the SFO, of the options granted to her by the Company under the share option scheme adopted by the Company on August 10, 2018 (the “**Pre-IPO Share Option Scheme**”).

Save as disclosed above, as at the date of this announcement, Dr. Qian (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO; and (iv) does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries.

Dr. Qian has confirmed that she has obtained legal advice from a firm of solicitors under Rule 3.09D of the Listing Rules and has confirmed that she understood her obligations as a Director of the Company.

Save as disclosed above, there is no other matter in relation to the appointment of Dr. Qian that needs to be brought to the attention of the Shareholders or the Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

III. APPOINTMENT OF VICE PRESIDENTS

In addition to the appointment of Dr. Qian as a vice president of the Company, the board is pleased to announce that Mr. Li Yunfeng (“**Mr. Li**”) will also be appointed as a vice president of the Company and he no longer holds the position of chief financial officer of the Company with effect from July 10, 2024.

The biographical details of Mr. Li are set out below.

Mr. Li Yunfeng (李雲峰), aged 47, and was appointed as an executive Director since July 20, 2018. He is primarily responsible for overseeing the management of market development, investment and legal work of our Group. Mr. Li joined our Group and served as a deputy general manager of Taizhou Pharmaceutical since March 2016, and was appointed as a director of Taizhou Pharmaceutical and Shengheng Biotechnology in August 2018 and November 2019, respectively.

Mr. Li has over 20 years of experience in the biotechnology industry, which in the Directors' view, enables him to competently carry out responsibilities in our Group. From January 2002 to June 2009, and from July 2010 to November 2012, Mr. Li was employed by Shanghai CP Guojian Pharmaceutical Co., Ltd. (上海中信國健藥業股份有限公司) (currently known as Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (三生國健藥業(上海)股份有限公司)) as a deputy general manager. Mr. Li worked as a deputy general manager at Shanghai National Engineering Research Center of Antibody Medicine Co., Ltd. (上海抗體藥物國家工程研究中心有限公司) from July 2009 to June 2010 and a general manager of Shanghai Lansheng Guojian Pharmaceutical Co., Ltd. (上海蘭生國健藥業有限公司) (currently known as Shanghai Xingsheng Pharmaceutical Co., Ltd. (上海興生藥業有限公司)) from December 2012 to March 2016. Mr. Li served as a deputy general manager of Zhangjiang Biotechnology from March 2016 to July 2017. He also worked as a deputy general manager of Biomabs and MTJA respectively from March 2016 to August 2018.

Mr. Li obtained a bachelor degree in international economics from Nanjing Normal University (南京師範大學) in July 1998.

Mr. Li was a legal representative of the following dissolved company, which was incorporated in the People's Republic of China ("PRC"), prior to its dissolution:

Name of Company	Place of incorporation	Nature of business	Means of dissolution	Date of dissolution	Reasons of dissolution
Jiangsu Guojian Biotechnology Co., Ltd (江蘇國健生物技術有限公司)	PRC	Pharmaceutical manufacturing industry	Deregistration	September 29, 2011	Cessation of business

Mr. Li confirmed that the above company was solvent at the time when it was dissolved by way of deregistration. Mr. Li confirmed that there was no wrongful act on his part leading to the dissolution of Jiangsu Guojian Biotechnology Co., Ltd, and he is not aware of any actual or potential claim that has been or will be made against him as a result of the dissolution.

As at the date of this announcement, Mr. Li was deemed to be beneficially interested in 3,236,234 underlying Shares, representing approximately 0.08% of the issued share capital of the Company, within the meaning of Part XV of the SFO, representing the options granted to him by the Company under the Pre-IPO Share Option Scheme.

Save as disclosed above, as at the date of this announcement, Mr. Li (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO; and (iv) does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries.

Save as disclosed above, there is no other matter in relation to the appointment of Mr. Li as vice president that needs to be brought to the attention of the Shareholders or the Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

IV. ACKNOWLEDGEMENT

The Board would also like to extend its warmest welcome to Mr. Cen and Dr. Tao in joining the Board.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, July 10, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu as executive Directors; Mr. Jiao Shuge and Mr. Cen Jialin as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun, Mr. Leung, Louis Ho Ming and Dr. Tao Qian as independent non-executive Directors.

* *For identification purpose only*